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relevaNCe for soCiety
Today, more than 44.4 million people suffer from dementia [1]. This number will 
increase to about 135.5 million in 2050. Every year 7.7 million new cases of dementia 
are diagnosed, implying that there is a new case of dementia somewhere in the world 
every four seconds. Dementia has emerged as one of the leading health problems of our 
time and has been recently recognized as one of the major threats to world population 
[2]. Symptoms include progressive loss of memory, impaired reasoning and judgement, 
difficulties paying attention, communication problems and various non-cognitive 
symptoms, ultimately leading to disability and need for care.
Most individuals diagnosed with dementia are 65 years or older, although there is a 
growing awareness of cases that start before the age of 65 [1]. Demographic ageing is a 
worldwide process resulting from constantly improving health care systems. The fastest 
growth in the elderly population is taking place in China, India, and their South Asian 
and Pacific neighbors. In 2010, the total estimated worldwide cost of dementia was 
US$604 billion, which equals to around 1% of the world’s gross domestic product [3]. 
About 70% of the costs occur in Western Europe and North America. Statisticians even 
claim, that if dementia care would represent a country, it would be the world’s 18th 
largest economy, ranking between Turkey and Indonesia [1].
Unfortunately, despite decades of research, we are still in need of an effective therapy 
for dementia, symptomatic or curative. There are 5 approved drugs on the market, 
which either modulate the cholinergic system by inhibiting acetylcholinesterase or 
reduce glutamate by antagonising specific glutamate receptors [4]. These pharmaco-
logical interventions, however, have limited efficacy and severe-side effects for patients; 
therefore, we are in need of new, effective, and safe alternative treatment options.
 Recently, deep brain stimulation (DBS) has shown to have beneficial effects across 
memory and cognitive networks. A first evidence for this emerged when Hamani and 
colleagues stimulated the fornix/hypothalamus area in a patient suffering from morbid 
obesity [5]. In this specific case, DBS generated detailed autobiographical memories 
in the patient. Based on this case-observation, the same group performed a phase-I 
trial in patients with Alzheimer’s Disease (AD) [6]. Indeed, memory tests confirmed 
possible improvements and/or slowing in the rate of cognitive decline in some patients 
following chronic DBS of 12 months.
Despite the encouraging results of the clinical trials presented above, basic neural 
and chemical mechanisms underlying DBS are still debated [7]. One approach to ad-
dress these issues is to investigate the effects by stimulating homologous regions in 
experimental animal models [8].
Therefore, the studies described in this dissertation aimed at investigating which DBS 
target structures and stimulation parameters produce the most beneficial effects in an 
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experimental model of dementia. In addition, the present dissertation also describes 
potential mechanisms of action of DBS with regard to memory restoration. Only 
through understanding the mechanisms, DBS therapy in dementia patients can be 
fine-tuned to produce the best possible symptom relief currently available.
target grouPs
Target groups of the research presented in this dissertation are broad.
The first target audience entails the patients and their caregivers. As described above, 
effective dementia treatment represents a major unmet medical need at present. The 
quality of life of millions of patients as well as their caregivers significantly decreases 
in the progression of the disease. The consequences usually include a substantial de-
cline in family’s health and emotional well-being. Unfortunately, drug-based research 
activities in the last years have not resulted in breakthroughs in treating patients with 
dementia. In this respect, DBS might open new ways for alternative, non-drug based 
treatment in dementia-related disorders. In line with this, by examining the effects of 
DBS in an experimental model of dementia, we might have established the groundwork 
of new treatment options for not only for patients with dementia, but also for patients 
suffering from other cognitive impairing CNS diseases. In fact, many neurological and 
psychiatric conditions are constituted by cognitive disorders, for example patients with 
schizophrenia, attention-deficit hyperactivity disorder, depression and addiction often 
suffer from comorbid cognitive impairment. Thus, the present dissertation provides 
primary findings, which help to elucidate how DBS could potentially improve cognitive 
functions in dementia and other neurological and psychiatric diseases.
Coherent to this, the general public forms another target audience. Dementia has 
been defined as the most costly disease of our time. Treatment costs are covered by 
health insurances, affected individuals, their families and private insurances. In this re-
spect, alleviating symptoms of dementia by means of DBS, would not only improve the 
quality of life of patients and caregivers, it would also provide a major financial relief 
for health care costs. Thus, delaying institutionalisation of patients by means of DBS 
can have an impact on economy and society, because patients function independently 
for longer, i.e. they can work, consume and invest for longer.
The third target group comprises the scientific critical mass. The findings of which 
brain region target for DBS produces most beneficial effects with regard to memory 
restoration might be of interest to neurosurgeons. Out of all structures within the cir-
cuit of Papez, the studies described in this dissertation, and other studies indicate that 
the fornix is the most relevant one for dementia therapy [9, 10]. Finally, the academic 
community as well as neuromodulation companies might profit from findings within 
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this dissertation. For example, there is an increasing awareness for the necessity to 
develop adaptive DBS systems (i.e., closed-loop), which prevent side-effects caused by 
overstimulation. Closed-loop feedback systems are latest advances in DBS therapy for 
epilepsy, but have not yet been developed for AD.
aCtivity/ProduCts
The major product/finding which can be derived by studies in this dissertation is that 
DBS might constitute an alternative treatment option for patients with dementia-related 
disorders. Results of the current dissertation provide evidence, that the fornix is the 
most suitable DBS target structure within the circuit of Papez to restore memory loss 
in an experimental rat model of dementia. The effects of fornix DBS are accompanied 
by selective neural activation in the hippocampus as well as increased hippocampal 
acetylcholine levels and no long-term neurogenic changes. In fact, the experiments in 
Chapter 9 have indicated that adaptive mechanism-based DBS might be necessary to 
maintain beneficial memory effects.
Chapter 3 of this dissertation also sheds light on the fact that up to now, most DBS 
studies in psychiatric disorders were first conducted in humans. Since the clinical 
data and the findings from animal studies show similarities, animal models can be of 
important value to find potential new DBS targets and settings for memory restoration. 
Close collaboration between basic scientists and clinicians has led to a successful imple-
mentation of preclinical findings to clinical DBS over the past years. For a successful 
treatment, such as DBS in patients with Parkinson’s disease, a solid scientific base is 
needed. Increased understanding of basal ganglia function from studies in translational 
Parkinson’s disease models [11, 12] paved the way for the clinical application of this 
method [13] and became the most successful application of DBS thus far.
iNNovatioN
The studies of this dissertation have been innovative for several reasons. This work com-
prised in-depth investigation of the recently introduced concept of treating demented 
patients with DBS. This is a novel concept that might provide more rapid and robust 
therapies for patients with dementia. Furthermore, a multi-level, interdisciplinary ap-
proach was applied: bilateral DBS in freely moving animals, behavioral assessment, 
microdialysis and histology. This multi-level approach helped to understand if and 
how memory can be improved by DBS, in particular what the potential mechanisms 
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of action are. Novel mechanisms of DBS were identified, which might facilitate the 
treatment and management of patients with dementia in the future.
imPlemeNtatioN
In line with the abovementioned relevance of this project for patients, society and the 
scientific community, the implementation of the knowledge generated by this disser-
tation is again at various levels. Therefore, novel insights will be shared with patient 
organizations, health care professionals and scientific societies. From an academic per-
spective, results have been or will be published in peer-reviewed international journals 
and are presented at national and international conferences.
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